Diffuse Intrinsic Pontine Gliomas-current Management and New Biologic Insights. Is There a Glimmer of Hope?

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2017 Apr 4

PMID 28371920

Citations 71

Authors

Kenneth J Cohen

Nada Jabado

Jacques Grill

Affiliations

Soon will be listed here.

Abstract

Diffuse intrinsic pontine glioma (DIPG) has proven to be one of the most challenging of all pediatric cancers. Owing to a historical reticence to obtain tumor tissue for study, and based on an erroneous assumption that the biology of DIPG would mirror that of supratentorial high-grade astrocytomas, innumerable studies have been undertaken-all of which have had a negligible impact on the natural history of this disease. More recently, improvements in neurosurgical techniques have allowed for the safe upfront biopsy of DIPG, which, together with a wider use of autopsy tissue, has led to an evolving understanding of the biology of this tumor. The discovery of a recurrent somatic gain-of-function mutation leading to lysine 27 to methionine (p.Lys27Met, K27M) substitution in histone 3 variants characterizes more than 85% of DIPG, suggesting for the first time the role of the epigenome and histones in the pathogenesis of this disease, and more unified diagnostic criteria. Along with further molecular insights into the pathogenesis of DIPG, rational targets are being identified and studied in the hopes of improving the otherwise dismal outcome for children with DIPG.

Citing Articles

Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review.

Lo Greco M, Marano G, La Rocca M, Acquaviva G, Milazzotto R, Liardo R Cancers (Basel). 2025; 17(3).

PMID: 39941789 PMC: 11815860. DOI: 10.3390/cancers17030420.

Pediatric spinal high-grade glioma in the pediatric precision oncology registry INFORM: Identification of potential therapeutic targets.

Pfaff E, Schramm K, Blattner-Johnson M, Jones B, Stark S, Balasubramanian G Neurooncol Adv. 2025; 7(1):vdae185.

PMID: 39896072 PMC: 11783565. DOI: 10.1093/noajnl/vdae185.

Deep mutual learning on hybrid amino acid PET predicts H3K27M mutations in midline gliomas.

Yuan Y, Li G, Mei S, Hu M, Chu Y, Hsu Y NPJ Precis Oncol. 2024; 8(1):274.

PMID: 39587279 PMC: 11589770. DOI: 10.1038/s41698-024-00760-1.

Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma.

Mbah N, Myers A, Sajjakulnukit P, Chung C, Thompson J, Hong H Nat Commun. 2024; 15(1):8983.

PMID: 39419964 PMC: 11487135. DOI: 10.1038/s41467-024-52973-4.

Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy.

Li Y, Zhao C, Ge J, Li C, Xue F, Qi S BMC Cancer. 2024; 24(1):754.

PMID: 38907215 PMC: 11193221. DOI: 10.1186/s12885-024-12373-9.

References

Negretti L, Bouchireb K, Levy-Piedbois C, Habrand J, Dhermain F, Kalifa C . Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience. J Neurooncol. 2011; 104(3):773-7. DOI: 10.1007/s11060-011-0542-4. View

Jones D, Hutter B, Jager N, Korshunov A, Kool M, Warnatz H . Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013; 45(8):927-32. PMC: 3951336. DOI: 10.1038/ng.2682. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Hochart A, Escande F, Rocourt N, Grill J, Koubi-Pick V, Beaujot J . Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma. Ann Clin Transl Neurol. 2015; 2(4):439-43. PMC: 4402089. DOI: 10.1002/acn3.184. View

Truffaux N, Philippe C, Paulsson J, Andreiuolo F, Guerrini-Rousseau L, Cornilleau G . Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Neuro Oncol. 2014; 17(7):953-64. PMC: 5654348. DOI: 10.1093/neuonc/nou330. View

Behjati S, Tarpey P, Presneau N, Scheipl S, Pillay N, Van Loo P . Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013; 45(12):1479-82. PMC: 3839851. DOI: 10.1038/ng.2814. View

Steffen-Smith E, Sarlls J, Pierpaoli C, Shih J, Bent R, Walker L . Diffusion tensor histogram analysis of pediatric diffuse intrinsic pontine glioma. Biomed Res Int. 2014; 2014:647356. PMC: 4071985. DOI: 10.1155/2014/647356. View

Sturm D, Witt H, Hovestadt V, Khuong-Quang D, Jones D, Konermann C . Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012; 22(4):425-37. DOI: 10.1016/j.ccr.2012.08.024. View

Monje M, Mitra S, Freret M, Raveh T, Kim J, Masek M . Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A. 2011; 108(11):4453-8. PMC: 3060250. DOI: 10.1073/pnas.1101657108. View

10.

Mishina Y, Crombie R, Bradley A, Behringer R . Multiple roles for activin-like kinase-2 signaling during mouse embryogenesis. Dev Biol. 1999; 213(2):314-26. DOI: 10.1006/dbio.1999.9378. View

11.

Chaikuad A, Alfano I, Kerr G, Sanvitale C, Boergermann J, Triffitt J . Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem. 2012; 287(44):36990-8. PMC: 3481300. DOI: 10.1074/jbc.M112.365932. View

12.

Bredlau A, Korones D . Diffuse intrinsic pontine gliomas: treatments and controversies. Adv Cancer Res. 2014; 121:235-259. DOI: 10.1016/B978-0-12-800249-0.00006-8. View

13.

Dhayalan A, Tamas R, Bock I, Tattermusch A, Dimitrova E, Kudithipudi S . The ATRX-ADD domain binds to H3 tail peptides and reads the combined methylation state of K4 and K9. Hum Mol Genet. 2011; 20(11):2195-203. PMC: 3090196. DOI: 10.1093/hmg/ddr107. View

14.

Dhermain F, Hau P, Lanfermann H, Jacobs A, van den Bent M . Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010; 9(9):906-20. DOI: 10.1016/S1474-4422(10)70181-2. View

15.

Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C . Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014; 128(4):573-81. PMC: 4159563. DOI: 10.1007/s00401-014-1319-6. View

16.

Poussaint T, Kocak M, Vajapeyam S, Packer R, Robertson R, Geyer R . MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol. 2011; 13(4):417-27. PMC: 3064695. DOI: 10.1093/neuonc/noq200. View

17.

Atak Z, Gianfelici V, Hulselmans G, De Keersmaecker K, Devasia A, Geerdens E . Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 2013; 9(12):e1003997. PMC: 3868543. DOI: 10.1371/journal.pgen.1003997. View

18.

Venneti S, Garimella M, Sullivan L, Martinez D, Huse J, Heguy A . Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol. 2013; 23(5):558-64. PMC: 3701028. DOI: 10.1111/bpa.12042. View

19.

Fontebasso A, Gayden T, Nikbakht H, Neirinck M, Papillon-Cavanagh S, Majewski J . Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors. Acta Neuropathol. 2014; 128(5):615-27. PMC: 4201756. DOI: 10.1007/s00401-014-1325-8. View

20.

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View